ANDREA MI WILD-GINGELESKI

Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner BEDFORD, VA NPI 1447923719

General Payments — all program years on this page

$632.05

  • Category: General Payments
  • Program years: PY2023–2024
  • Record count: 32
  • As of (CMS publication): 2026-01-23

Latest program year (PY2024): $409.58 across 19 records · disputed records: 0

Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.

How this figure is calculated
  • The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
  • Methodology & Data — sourcing, labeling, and limitations.

By nature of payment

Latest program year (PY2024) · sorted by reported total.

Nature of paymentAmountRecords
Food and Beverage $409.5819

By paying entity

Latest program year (PY2024) · sorted by reported total.

Paying entityAmountRecords
Acerta Pharma LLC $137.105
Novo Nordisk AS $92.765
PFIZER INC. $43.853
ABBVIE INC. $34.251
Alkermes, Inc. $23.401
Lilly USA, LLC $22.721
SI-BONE, INC. $20.061
Merck Sharp & Dohme Corporation $19.941
Astellas Pharma US Inc $15.501

By program year

Program yearAmountRecords
2023 $222.4713
2024 $409.5819

Records — PY2024 (19)

Record IDPaying entityAmountDate Nature of paymentDispute statusPublishedSource
1100272096 Novo Nordisk Inc $18.97 08/14/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1100331448 Novo Nordisk Inc $16.46 08/13/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1100467254 Novo Nordisk Inc $16.01 10/22/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1100518753 Novo Nordisk Inc $16.55 03/19/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1100579906 Novo Nordisk Inc $24.77 02/12/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1104210507 AstraZeneca Pharmaceuticals LP $13.94 06/27/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1104327736 AstraZeneca Pharmaceuticals LP $13.24 07/31/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1104533236 AstraZeneca Pharmaceuticals LP $73.96 03/05/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1105629344 AstraZeneca Pharmaceuticals LP $16.65 01/29/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1105648474 AstraZeneca Pharmaceuticals LP $19.31 05/29/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1108410679 ABBVIE INC. $34.25 08/16/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1120069239 SI-BONE, INC. $20.06 05/22/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1120620026 Alkermes, Inc. $23.40 04/09/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1131138138 PFIZER INC. $14.79 01/22/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1131553194 PFIZER INC. $15.35 05/08/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1132133267 PFIZER INC. $13.71 10/02/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1135447461 Lilly USA, LLC $22.72 08/21/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1139497416 Astellas Pharma US Inc $15.50 04/04/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1141918644 Merck Sharp & Dohme LLC $19.94 07/17/2024 Food and Beverage Undisputed 01/23/2026 View at CMS

Provenance & corrections

  • Dataset: CMS Open Payments — General Payments
  • Source: CMS Open Payments dataset (bulk file)
  • Publisher of source data: Centers for Medicare & Medicaid Services
  • Generated from: OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.